Alexion Pharmaceuticals, INC.: directors' dealings · United States · SEC (Form 4)

About Alexion Pharmaceuticals, INC.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company built around a highly specialized rare-disease franchise. For equity investors, the key point is that Alexion is now part of Alexion, AstraZeneca Rare Disease, following AstraZeneca’s acquisition of Alexion in July 2021. The original Alexion Pharmaceuticals entity was a U.S.-based public company that traded on the NASDAQ before being taken private; therefore, references to Alexion in SEC materials, including Form 4 insider transaction filings, typically relate to the company’s legacy corporate footprint or securities history rather than an actively listed standalone issuer today. The company remains a meaningful brand and operating platform inside AstraZeneca’s rare-disease business. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals?utm_source=openai)) Alexion was founded in the late 1990s and developed a strong reputation as a pioneer in orphan drugs and ultra-rare disease therapies. Its business model has long focused on identifying severe conditions with limited or no treatment options, then building a clinical, regulatory, and commercial franchise around targeted biologics. That strategy helped Alexion establish a durable niche in rare disease, especially through its expertise in complement biology and patient-centric development. The company’s public materials emphasize a “scientific firsts” heritage, continuous innovation, and close collaboration with patients, advocacy groups, and research centers. ([alexion.com](https://alexion.com/our-company/about-us)) The commercial portfolio associated with Alexion in the United States includes Soliris, Ultomiris, Strensiq, Kanuma, and Koselugo. These medicines span multiple rare-disease categories, including hematology, nephrology, neurology, bone metabolism, endocrinology, cardiology, and certain rare cancers. Strategically, this mix matters because it broadens the revenue base while preserving the company’s core advantage: deep expertise in diseases where scientific complexity, specialist prescribing, and reimbursement dynamics create high barriers to entry. Competition is typically limited to a small set of highly specialized players, but pricing discipline, market access, and clinical differentiation remain critical. ([alexion.com](https://alexion.com/worldwide/united-states/)) Geographically, Alexion operates as a global rare-disease platform under AstraZeneca’s umbrella. Its U.S. office and global/regional headquarters are listed in Boston, Massachusetts, underscoring the importance of the American market as both a commercial base and an R&D anchor. At the same time, the business is designed for international reach, leveraging AstraZeneca’s broader footprint to expand access to rare-disease medicines across many countries. Recent company messaging continues to highlight pipeline expansion, next-generation complement inhibitors, and potentially curative modalities, which suggests that innovation remains central to the long-term investment case. ([alexion.com](https://alexion.com/worldwide/united-states/)) Overall, Alexion remains a high-quality rare-disease asset in the U.S. healthcare universe. It combines a premium niche position, a strong scientific heritage, and a globally scalable operating model inside AstraZeneca. For investors, the profile is typically characterized by defensive demand characteristics, specialist leadership, and continued R&D optionality in ultra-rare diseases. ([astrazeneca.com](https://www.astrazeneca.com/our-company.html?utm_source=openai))